However, it has been shown that ICIs interrupt immune suppression and activate CD8-positive T lymphocytes in the tumor microenvironment, and these activated CD8-positive T-lymphocytes attack not only the tumors but also cause immune-related adverse events (irAEs) (29). This evidence concerns the gene CD8A and neoplasm.